Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LOX | P28300 | 1/20 | 0.52 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31669110 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2POLBHRH3ALDH1A1RECQL | |
| SCHEMBL7606866 | 0.98 | SMN1; SMN2 (0.57) | SMN1; SMN2POLBHRH3ALDH1A1RECQL | |
| SCHEMBL23358024 | 0.96 | RECQL (0.52) | SMN1; SMN2POLBHRH3ALDH1A1RECQL | |
| SCHEMBL29944490 | 0.96 | RECQL (0.52) | SMN1; SMN2POLBHRH3ALDH1A1RECQL | |
| SCHEMBL937665 | 0.85 | HRH3 (0.54) | SMN1; SMN2HRH3ALDH1A1RECQLKDM4E | |
| SCHEMBL17331777 | 0.85 | MC4R (0.54) | ALDH1A1RECQLKDM4ELOXLOXL3 | |
| SCHEMBL12538821 | 0.85 | CXCR4 (0.61) | HRH3RECQLLOXLOXL3LOXL2 | |
| SCHEMBL14640057 | 0.84 | CXCR4 (0.76) | HRH3CXCR4TDP1 | |
| SCHEMBL12538740 | 0.82 | KMT2A (0.54) | ALDH1A1RECQLLOXLOXL3LOXL2 | |
| SCHEMBL12538871 | 0.79 | CYP3A4 (0.54) | SMN1; SMN2ALDH1A1RECQLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858938-B2 | Imidazo-fused heterocycles and uses thereof | LIGAND PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858938-B2 | Imidazo-fused heterocycles and uses thereof | LIGAND PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-04-21 | — | — | US | disclosed |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-04-21 | — | — | US | disclosed |
| US-11186593-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186593-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| WO-2012068546-A1 | HETEROCYCLE AMINES AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012068546-A1 | HETEROCYCLE AMINES AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20110130394-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| EP-2315761-A1 | PHARMACEUTICAL COMPOUNDS | Sentinel Oncology Limited (GB) | 2011-05-04 | — | — | EP | disclosed |
| WO-2011011303-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011011303-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2010007374-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130394-A1 | PHARMACEUTICAL COMPOUNDS | NR2C2, NR3C2, NR0B2 | SMN1; SMN2 2784/4885POLB 2773/4885HRH3 166/4885 |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC5, HDAC3 | SMN1; SMN2 3345/4885POLB 2046/4885HRH3 70/4885 |
| US-11773110-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | SMN1; SMN2 1082/4885POLB 2167/4885HRH3 15/4885 |
| US-11858938-B2 | Imidazo-fused heterocycles and uses thereof | PAICS, ABL1, IDH3A | SMN1; SMN2 511/4885POLB 2551/4885HRH3 264/4885 |
| US-11186593-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | SMN1; SMN2 1082/4885POLB 2167/4885HRH3 15/4885 |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | SMN1; SMN2 1851/4885POLB 1584/4885HRH3 4242/4885 |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | SMN1; SMN2 1082/4885POLB 2167/4885HRH3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.